Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD, Li JX, Liu J, Wang HM, Zhou GH, Li J, Wu D, Chen X, Feng Y, Qi XY, Wang X, Gou JB, Ma TL, Yang XY, Xu LF, Wan P, Zhu T, Wang ZF, Zhu FC; CanSino COVID-19 Study Group.
Wu JD, et al. Among authors: ma tl.
Lancet Infect Dis. 2023 Sep;23(9):1020-1030. doi: 10.1016/S1473-3099(23)00199-8. Epub 2023 May 19.
Lancet Infect Dis. 2023.
PMID: 37216958
Clinical Trial.